Exelixis Reveals Preliminary Financial Outcomes for 2024 and Sets Ambitious Goals for 2025
January 13, 2025 - 02:56
ALAMEDA, Calif., January 12, 2025—Exelixis, Inc. has announced its preliminary unaudited financial results for the fiscal year 2024, alongside financial guidance for the upcoming fiscal year 2025. The company is optimistic about the potential for significant advancements in clinical and regulatory efforts, particularly concerning its cabozantinib franchise.
In 2025, Exelixis plans to focus on executing its clinical programs and anticipates multiple data readouts for zanzalintinib, as well as developments across its diverse pipeline of small molecules and biotherapeutics. The company aims to leverage its existing assets while exploring new opportunities to enhance its market position.
With a clear strategy in place, Exelixis is poised for a year of growth, innovation, and impactful milestones that could shape the future of its therapeutic offerings. The commitment to advancing patient care remains at the forefront of Exelixis's mission as it navigates the challenges and opportunities ahead.
MORE NEWS
May 10, 2026 - 03:00
Clean Harbors Q1 Earnings Call HighlightsClean Harbors (NYSE:CLH) reported stronger-than-expected financial results for the first quarter of 2026, prompting the company to lift its full-year guidance. Executives pointed to improved...
May 9, 2026 - 04:23
What is Considered a Good Dividend Stock? 2 Financial Stocks That Fit the BillWhen investors look for dividend stocks, the goal is usually a mix of steady income and long-term capital appreciation. A good dividend stock typically offers a sustainable payout ratio, consistent...
May 8, 2026 - 20:55
BOK Financial's Dividend Decision and Buyback Pause: What It Means for InvestorsBOK Financial Corporation has declared a regular quarterly cash dividend of $0.63 per share, payable on May 27, 2026, to shareholders on record as of the May 13 ex-dividend date. The announcement...
May 8, 2026 - 10:34
Stock market today: Dow, S&P 500, Nasdaq futures slip as Iran and the US ramp up Hormuz aggressionStock futures pointed lower early Monday as renewed military posturing between the United States and Iran rattled investors, erasing the cautious optimism that had built up during a week of...